Crispr Therapeutics shares tumble after significant earnings miss
In a year marked by significant volatility, Dun & Bradstreet Holdings Inc. (DNB) stock has recorded a new 52-week low, dipping to $8.01. This latest price level reflects a stark contrast to the company’s performance over the past year, with the stock witnessing a decline of 21.62%. Investors have been closely monitoring DNB’s trajectory as it navigates through a complex economic landscape, with this new low serving as a critical indicator of the company’s current market position and investor sentiment. The 52-week low also underscores the challenges faced by DNB in a year that has tested the resilience of many firms across various sectors. While currently showing losses, InvestingPro analysis indicates the company is expected to return to profitability this year, with analysts forecasting positive earnings. Discover 8 more exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Dun & Bradstreet reported its fourth-quarter 2024 earnings, which did not meet analysts’ expectations for both earnings per share (EPS) and revenue. The company posted a revenue of $632 million for the quarter, reflecting less than 1% growth, and a full-year revenue of $382.002 million, marking a 3% increase. Despite the revenue shortfall, the company remains focused on strategic initiatives and product innovations for long-term growth, including AI-powered solutions and risk analytics. Analysts from Needham and Raymond (NSE:RYMD) James have both adjusted their price targets for Dun & Bradstreet shares to $14.00, down from $17.00 and $19.00 respectively, while maintaining Buy and Strong Buy ratings. The analysts cited the company’s ongoing strategic review and the termination of two low-margin partnerships as factors impacting recent performance. Dun & Bradstreet plans to conclude its strategic review in the first quarter of 2025, which could potentially lead to significant corporate actions. Meanwhile, the company projects revenue growth of 2.5% to 5% for 2025, with an adjusted EBITDA guidance between $955 million and $985 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.